TY - JOUR AU - Lisberg, Aaron AU - Garon, Edward B. PY - 2017 TI - Epidermal growth factor tyrosine kinase inhibitor therapy inferior to second-line chemotherapy in EGFR wild-type non-small cell lung cancer patients: results of French nationwide observational study JF - Translational Lung Cancer Research; Vol 6, Supplement 1 (December 21, 2017): Translational Lung Cancer Research Y2 - 2017 KW - N2 - In the recent issue of The European Respiratory Journal , Tomasini et al. report on an observational study comparing the clinical, biological, treatment and outcome data for epidermal growth factor wild-type (EGFR-wt) advanced non-small cell lung cancer (NSCLC) patients who received second-line treatment with an EGFR tyrosine kinase inhibitor (TKI) versus those that received second-line chemotherapy, collected in France over a 1 year period (1). Their central finding, that clinical outcomes with second-line EGFR TKI therapy in EGFR-wt patients were inferior to those with second-line chemotherapy, underscores the ineffectual nature of the treatment of EGFR-wt NSCLC with an EGFR TKI. UR - https://tlcr.amegroups.org/article/view/17380